Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 15

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 15
---
 consolidated balance sheet information as of March 31, 2025 and December 31, 2024 from our interim unaudited consolidated financial statements and audited consolidated financial statements, respectively, included elsewhere in this prospectus. Our consolidated financial statements have been prepared in accordance with GAAP and our consolidated financial statements are presented in U.S. dollars, except where indicated otherwise. Our historical results are not necessarily indicative of the results that should be expected in any future period.

<div align='center'>CONSOLIDATED STATEMENT OF OPERATIONS</div>

| Operating expenses                                                         |   | Three Months  Ended March 31, 
                          2025 |   |   |       2024 |   |
|:---------------------------------------------------------------------------|:--|------------------------------:|:--|:--|-----------:|:--|
| General and administrative                                                 | $ |                     3,120,060 |   | $ |  1,385,981 |   |
| Research and development                                                   |   |                     2,006,214 |   |   |    321,377 |   |
| Total operating expenses                                                   |   |                     5,126,274 |   |   |  1,707,358 |   |
| Loss from operations                                                       |   |                    (5,126,274 | ) |   | (1,707,358 | ) |
| Other income                                                               |   |                               |   |   |            |   |
| Finance income                                                             |   |                        23,866 |   |   |          - |   |
| Total other income                                                         |   |                        23,866 |   |   |          - |   |
| Net loss and comprehensive loss for the year                               | $ |                    (5,102,408 | ) | $ | (1,707,358 | ) |
| Net loss per share attributable to common shareholders - basic and diluted | $ |                         (0.42 | ) | $ |      (0.21 | ) |
| Weighted average number of common shares outstanding - basic and diluted   |   |                    12,240,437 |   |   |  8,076,673 |   |

<div align='center'>- 7 -

CONSOLIDATED BALANCE SHEET DATA</div>

|                                                                                                                                                                        |   | March 31, 2025 |   |   | December 31, 2024 |   |
|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--|---------------:|